Trial reportBMC medicine2017
S100β as a serum marker in endocrine resistant breast cancer.
Trial report in BMC medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01840293 (Breast Cancer Proteomics and Molecular Heterogeneity), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Breast Cancer Proteomics and Molecular Heterogeneity
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- Influence of Calcium Ions on the Membrane Binding of S100B Protein.Langmuir : the ACS journal of surfaces and colloids · 2025Article
- Molecular and morphological alterations in breast tissue of transgender patients undergoing dihydrotestosterone therapy.PloS one · 2025Article
- Construction and validation of an aging-related gene signature for prognosis prediction of patients with breast cancer.Cancer reports (Hoboken, N.J.) · 2023Article
- 3D Cell Culture Systems: Tumor Application, Advantages, and Disadvantages.International journal of molecular sciences · 2021Review
- A novel immune-related prognostic index for predicting breast cancer overall survival.Breast cancer (Tokyo, Japan) · 2021Article
- ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis.BMC medicine · 2020Article
- An immune-related prognostic signature for predicting breast cancer recurrence.Cancer medicine · 2020Article
- Friend or Foe: S100 Proteins in Cancer.Cancers · 2020Review
- Dysregulation of TLR2 Serves as a Prognostic Biomarker in Breast Cancer and Predicts Resistance to Endocrine Therapy in the Luminal B Subtype.Frontiers in oncology · 2020Article
- Novel Strategies for Cancer Treatment: Highlights from the 55th IACR Annual Conference.Cancers · 2019Article
- S100 Proteins in Acute Myeloid Leukemia.Neoplasia (New York, N.Y.) · 2018Review
- Multifarious diagnostic possibilities of the S100 protein family: predominantly in pediatrics and neonatology.World journal of pediatrics : WJP · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndocrine therapy is standard treatment for estrogen receptor (ER)-positive breast cancer. However, its efficacy is limited by intrinsic and acquired resistance. Here the potential of S100β as a biomarker and inhibition of its signaling network as a therapeutic strategy in endocrine treated patients was investigated.
methodsThe expression of S100β in tissue and serum was assessed by immunohistochemistry and an enzyme-linked immunosorbent assay, respectively. The S100β signaling network was investigated in cell line models of endocrine resistance by western blot, PCR, immunoprecipitation, and chromatin-immunoprecipitation. Endocrine resistant xenografts and tumor explants from patients with resistant tumors were treated with endocrine therapy in the presence and absence of the p-Src kinase inhibitor, dasatinib.
resultsTissue and serum levels of S100β were found to predict poor disease-free survival in endocrine-treated patients (n = 509, HR 2.32, 95% CI is 1.58-3.40, p < 0.0001 and n = 187, HR 4.009, 95% CI is 1.66-9.68, p = 0.002, respectively). Moreover, elevated levels of serum S100β detected during routine surveillance over the patient treatment period significantly associated with subsequent clinically confirmed disease recurrence (p = 0.019). In vivo studies demonstrated that endocrine treatment induced transcriptional regulation of S100β which was successfully disrupted with tyrosine kinase inhibition. In endocrine resistant xenografts and tumor explants from patients with endocrine resistant breast cancer, combined endocrine and dasatinib treatment reduced tumor proliferation and down-regulated S100β protein expression in comparison to endocrine treatment alone.
conclusionsS100β has potential as a new surveillance tool for patients with ER-positive breast cancer to monitor ongoing response to endocrine therapy. Moreover, endocrine resistant breast cancer patients with elevated S100β may benefit from combined endocrine and tyrosine-kinase inhibitor treatment.
trial registrationClinicalTrials.gov, NCT01840293 ). Registered on 23 April 2013. Retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.